دورية أكاديمية
Donor's age influences outcome in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide - a single center experience.
| العنوان: | Donor's age influences outcome in haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide - a single center experience. |
|---|---|
| المؤلفون: | Zielińska, Patrycja, Wieczorkiewicz-Kabut, Agata, Białas, Krzysztof, Koclęga, Anna, Gruenpeter, Karolina, Kopińska, Anna, Woźniczka, Krzysztof, Noster, Izabela, Gromek, Tomasz, Czyż, Jarosław, Grosicki, Sebastian, Wierzbowska, Agnieszka, Krzanowski, Jacek, Butrym, Aleksandra, Helbig, Grzegorz |
| المصدر: | Ann Hematol ; ISSN:1432-0584 |
| بيانات النشر: | Springer |
| سنة النشر: | 2024 |
| المجموعة: | PubMed Central (PMC) |
| مصطلحات موضوعية: | Acute leukemia, Donor, Haploidentical stem cell transplantation, Infections, Outcome, Posttransplant cyclophosphamide |
| الوصف: | Haploidentical stem cell transplantation (haplo-SCT) using post-transplantation cyclophosphamide (post-Cy) is considered a reasonable therapeutic option for patients who lack matched donor or who urgently need transplant procedure due to high risk disease. We analyzed the results of haplo-SCT performed in years 2018-2023. Eighty one patients (46 males) at median age of 52 years underwent haplo-SCT using peripheral blood as a stem cell source in most cases. Indications included hematological malignancies (acute leukemias in 88% of cases). In 25 cases (31%) transplantation was performed in relapsed/refractory disease. Majority of patients (61%) presented with very high and high disease risk index (DRI). Conditioning regimens were as follows: nonmyeloablative - 46 cases (57%), myeloablative - in 18 (22%) and reduced intensity - 17(20%). 90% of patients engrafted. All patients received unified immunosuppressive treatment (post-Cy/TAC/MMF). Median follow-up time was 12 months The cumulative incidence of acute and chronic GVHD was 37.5% and 37.6%, respectively. Estimated 2-year overall survival (OS) was 43.1% and donor's age was the only factor influencing survival. The 2-year progression-free survival (PFS) was 42.5%, whereas relapse incidence (RI) - 35%. The cumulative incidence of non-relapse mortality (NRM) was 44% and was mostly due to infections. Haplo-SCT is a feasible treatment option for hematological patients. Younger donor improves post-transplant survival. Strategies to reduce infection-related mortality and relapse rate remain a challenge. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| العلاقة: | https://doi.org/10.1007/s00277-024-05848-zTest; https://pubmed.ncbi.nlm.nih.gov/38878171Test |
| DOI: | 10.1007/s00277-024-05848-z |
| الإتاحة: | https://doi.org/10.1007/s00277-024-05848-zTest https://pubmed.ncbi.nlm.nih.gov/38878171Test |
| حقوق: | © 2024. The Author(s). |
| رقم الانضمام: | edsbas.5E329E74 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1007/s00277-024-05848-z |
|---|